Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Targeting prion protein interactions in cancer

Texto completo
Autor(es):
Santos, Tiago G. [1, 2, 3] ; Lopes, Marilene H. [2, 3, 4] ; Martins, Vilma R. [1, 2, 3]
Número total de Autores: 3
Afiliação do(s) autor(es):
[1] AC Camargo Canc Ctr, Int Res Ctr, Sao Paulo - Brazil
[2] Natl Inst Translat Neurosci, Sao Paulo - Brazil
[3] Natl Inst Oncogen CNPq MCT FAPESP, Sao Paulo - Brazil
[4] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Sao Paulo - Brazil
Número total de Afiliações: 4
Tipo de documento: Artigo Científico
Fonte: PRION; v. 9, n. 3, p. 165-173, MAY 4 2015.
Citações Web of Science: 14
Assunto(s):Neoplasias   Glioblastoma
Resumo

In recent years, prion protein (PrPC) has been considered as a promising target molecule for cancer therapies, due its direct or indirect participation in tumor growth, metastasis, and resistance to cell death induced by chemotherapy. PrPC functions as a scaffold protein, forming multiprotein complexes on the plasma membrane, which elicits distinct signaling pathways involved in diverse biological phenomena and could be modulated depending on the cell type, complex composition, and organization. In addition, PrPC and its partners participate in self-renewal of embryonic, tissue-specific stem cells and cancer stem cells, which are suggested to be responsible for the origin, maintenance, relapse, and dissemination of tumors. Interference with protein-protein interaction has been recognized as an important therapeutic strategy in cancer; indeed, the possible interference in PrPC engagement with specific partners is a novel strategy. Recently, our group successfully used that approach to interfere with the interaction between PrPC and HSP-90/70 organizing protein (HOP, also known as stress-inducible protein 1 - STI1) to control the growth of human glioblastoma in animal models. Thus, PrPC-organized multicomplexes have emerged as feasible candidates for anti-tumor therapy, warranting further exploration. (AU)

Processo FAPESP: 09/14027-2 - Mecanismos associados à função da proteína prion e seu ligante STI1/Hop: abordagens terapêuticas
Beneficiário:Vilma Regina Martins
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 11/13906-2 - Contribuição da co-chaperonina STI1 no desenvolvimento murino: células tronco embrionárias como modelo de estudo
Beneficiário:Marilene Hohmuth Lopes
Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores